Internship

Intern – Research Assistant

Global Medical Analytics, Real World Evidence, And Health Economics & Outcomes Research

Posted on 3/10/2025

Viatris

Viatris

10,001+ employees

Compensation Overview

$20 - $30/hr

Remote in USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • The successful candidate will have preferably completed a minimum of a Bachelor’s degree. Alternatively, the candidate is currently enrolled as a Junior or Senior as a Quantitative Science Major in an accredited university in the graduate school (Master’s or PhD degree candidate or a recent graduate) an accredited college or university.
  • A minimum 3.0 GPA (if calculated) in graduate school is preferred; however, a combination of experience and/or education will be taken into consideration.
  • Proficiency in Microsoft Office tools is required.
  • Proficiency in speaking, comprehending, reading, and writing English is required.
Responsibilities
  • Assisting in data, guidance, and software review;
  • Evidence generation;
  • Study ideation and execution;
  • Insights summary;
  • Quantitative research.
Desired Qualifications
  • Background in project management, public health, data science, statistics, or related disciplines is preferred.
  • Experience with real world data (e.g., claims data, electronic health records, surveys, and patient reported outcomes) and/or analytic software (e.g., Tableau, R, and Python) is a plus.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Simplify Jobs

Simplify's Take

What believers are saying

  • DOJ's clearance of Mylan improves Viatris' public image and reduces legal uncertainties.
  • Consistent dividend policy for five years reflects Viatris' financial stability.
  • Participation in major healthcare conferences boosts Viatris' investor engagement.

What critics are saying

  • Increased competition from biosimilars threatens Viatris' market share.
  • Expiration of key drug patents in 2025 may lead to revenue loss.
  • Reliance on international markets exposes Viatris to geopolitical risks.

What makes Viatris unique

  • Viatris bridges the gap between generics and branded drugs globally.
  • Exclusive licensing with Lexicon enhances Viatris' cardiovascular portfolio outside U.S. and Europe.
  • Viatris' commitment to innovation is evident in its cenerimod research for lupus treatment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Company News

PR Newswire
Mar 5th, 2025
Viatris To Present At The Barclays 27Th Annual Global Healthcare Conference

PITTSBURGH, March 5, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will present at the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, March 11, 2025. The company's fireside chat will begin at 2 p.m. ET.A live webcast of the event at can be found at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Feb 27th, 2025
Viatris Maintains Dividend Policy For 2025 And Announces Quarterly Dividend

PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on March 18, 2025, to shareholders of record at the close of business on March 10, 2025. This marks the fifth consecutive year the Company has paid a dividend.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Feb 3rd, 2025
Viatris To Report Fourth Quarter And Full Year 2024 Financial Results On February 27, 2025

PITTSBURGH, Feb. 3, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report financial results for the fourth quarter and full year 2024 on Thursday, February 27, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website.About ViatrisViatris Inc

PR Newswire
Oct 16th, 2024
Viatris Announces Exclusive Licensing Agreement With Lexicon Pharmaceuticals For Sotagliflozin In All Markets Outside Of The U.S. And Europe

Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases. Leverages Viatris' Unique Global Infrastructure and Expertise. Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications PITTSBURGH, Oct. 16, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has entered into an exclusive licensing agreement with Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) for sotagliflozin in all markets outside of the United States and Europe

INACTIVE